CEO of BioMarin Pharmaceutical Inc. (BMRN) Jean Jacques Bienaime sells 22,000 shares of BMRN on 04/27/2012 at an average price of $34.99 a share.

Biomarin Pharma has a market cap of $4.08 billion; its shares were traded at around $34.7 with and P/S ratio of 9.3.

This is the annual revenues and earnings per share of BMRN over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BMRN.

CEO Recent Trades:

• CEO Jean Jacques Bienaime sold 15,000 shares of BMRN stock on 03/09/2012 at the average price of 34.46. Jean Jacques Bienaime owns at least 114,093 shares after this. The price of the stock has increased by 0.7% since.
• CEO Jean Jacques Bienaime sold 1,000 shares of BMRN stock on 03/08/2012 at the average price of 35. Jean Jacques Bienaime owns at least 114,093 shares after this. The price of the stock has decreased by 0.86% since.
• CEO Jean Jacques Bienaime sold 1,000 shares of BMRN stock on 02/29/2012 at the average price of 36.26. Jean Jacques Bienaime owns at least 115,093 shares after this. The price of the stock has decreased by 4.3% since.
• CEO Jean Jacques Bienaime sold 5,000 shares of BMRN stock on 02/27/2012 at the average price of 35.64. Jean Jacques Bienaime owns at least 116,093 shares after this. The price of the stock has decreased by 2.64% since.
• CEO Jean Jacques Bienaime sold 5,000 shares of BMRN stock on 02/23/2012 at the average price of 35.31. Jean Jacques Bienaime owns at least 121,093 shares after this. The price of the stock has decreased by 1.73% since.

CFO Recent Trades:

• SVP, CFO Jeffrey H Cooper sold 83,036 shares of BMRN stock on 02/24/2012 at the average price of 35.07. Jeffrey H Cooper owns at least 40,104 shares after this. The price of the stock has decreased by 1.06% since.
• SVP, CFO Jeffrey H Cooper sold 2,500 shares of BMRN stock on 01/03/2012 at the average price of 34.75. Jeffrey H Cooper owns at least 40,104 shares after this. The price of the stock has decreased by 0.14% since.

This is the insider trade history vs. stock price of BMRN. For the complete insider trading history of BMRN, click here.

Directors and Officers Recent Trades:

• VP, Human Resources Mark Wood sold 1,853 shares of BMRN stock on 04/23/2012 at the average price of 34.54. Mark Wood owns at least 20,634 shares after this. The price of the stock has increased by 0.46% since.
• EVP, Chief Medical Officer Henry J Fuchs sold 7,691 shares of BMRN stock on 04/20/2012 at the average price of 35. Henry J Fuchs owns at least 28,920 shares after this. The price of the stock has decreased by 0.86% since.
• EVP, Chief Medical Officer Henry J Fuchs sold 5,000 shares of BMRN stock on 04/02/2012 at the average price of 34.08. Henry J Fuchs owns at least 36,611 shares after this. The price of the stock has increased by 1.82% since.
• VP, Human Resources Mark Wood sold 1,855 shares of BMRN stock on 03/22/2012 at the average price of 35.65. Mark Wood owns at least 20,634 shares after this. The price of the stock has decreased by 2.66% since.
• Director Pierre Lapalme sold 20,000 shares of BMRN stock on 02/28/2012 at the average price of 36.01. Pierre Lapalme owns at least 22,750 shares after this. The price of the stock has decreased by 3.64% since.

For the complete insider trading history of BMRN, click here.

Why CEOs Are Buying Stocks Of Their Own Companies?

1. As legendary investor Peter Lynch said: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."
2. TOP EXECUTIVES like CEOs and CFOs are savvy buyers of their companies' shares. One long-term study showed that they beat the market on average by six percentage points a year.
3. Another study found that the aggregated activities of insiders can serve as a good indicator to locate market bottoms. Insiders as a whole are smart investors of their own companies.

Click it to Check Out What the CEO Are Trading

More Gurufocus Links

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool